ArticlePloS one2026
Key molecular mechanisms of mitochondrial metabolic pathways in specific cell subpopulations of pancreatic cancer based on scRNA-seq and bulk RNA-seq.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) is a highly malignant tumor with increasing incidence, mortality, and a low five-year survival rate. Mitochondrial metabolic reprogramming plays a crucial role in tumor development, but the molecular mechanisms in different cell subpopulations of PC remain unclear. This study aims to integrate single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq to explore mitochondrial metabolism in PC.
methodsTranscriptome datasets (GSE183795, GSE16515, GSE197177, and TCGA-PAAD) were downloaded from the GEO and TCGA databases. Differentially expressed genes (DEGs) were identified using the limma package for bulk RNA-seq and the Seurat package for scRNA-seq. Weighted gene co-expression network analysis (WGCNA) was performed to identify key modules and hub genes. Machine learning algorithms screened key genes, and functional enrichment analysis was conducted using clusterProfiler. PPI, ceRNA, and transcription factor networks explored gene regulation. Immune infiltration analysis, drug prediction, and molecular docking were conducted on key genes. The prognostic value of the key genes was evaluated using clinical data from TCGA.
resultsA total of 1238 bulk RNA-DEGs and 8231 scRNA-DEGs in fibroblasts were identified. Integration of both datasets revealed 536 DEGs. WGCNA identified 6 modules associated with PC. By intersecting DEGs, hub genes, and mitochondrial metabolism-related genes, 18 candidate genes were obtained. These genes were enriched in glucose metabolism and mitochondrial outer membrane pathways. Three key genes (IFI27, PKM, and RSAD2) were selected using machine learning. PPI, ceRNA, and transcription factor networks provided regulatory insights. Immune infiltration analysis showed significant differences in immune cells, particularly in T cells CD4 memory resting and macrophages M2. Drug prediction and molecular docking identified potential drugs for these genes. Survival analysis indicated that high expression of these genes correlated with poor prognosis.
conclusionThis study integrates scRNA-seq and bulk RNA-seq data to identify three key genes (IFI27, PKM, and RSAD2) and their immune-related mechanisms in PC. These findings offer new insights into the pathogenesis and potential therapeutic targets for PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.